Ignite Creation Date:
2024-05-06 @ 8:24 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06374901
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-04-19
First Post:
2024-04-15
Brief Title:
Tislelizumab Combined With Neoadjuvant Chemotherapy Used in the Perioperative Treatment
Sponsor:
Xiangdong Cheng
Organization:
Zhejiang Cancer Hospital
Organization Data
Organization:
Zhejiang Cancer Hospital
Class:
OTHER
Study ID:
IRB-2024-311
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Xiangdong Cheng
Lead Sponsor Class:
OTHER
Responsible Party:
Xiangdong Cheng
Responsible Party Title:
Chief physician
Responsible Party Type:
SPONSOR_INVESTIGATOR
Responsible Party Affiliation:
Zhejiang Cancer Hospital
Old Name:
None
Old Organization:
None
Collaborators
| Name | Class |
|---|---|
| The Second Affiliated Hospital of Harbin Medical University | OTHER |
| Liaoning Tumor Hospital Institute | OTHER |
| Shanxi Province Cancer Hospital | OTHER |
| Sichuan Cancer Hospital and Research Institute | OTHER |